Alexion’s mission is to discover, develop and market innovative therapeutic products aimed at treating patients with serious unmet medical needs that involve hematologic disorders, acute cardiovascular conditions, inflammatory and immune-related disorders, and cancer through our proprietary discovery platform and also through collaboration with like-minded innovative scientists and companies worldwide. Currently, we have two internally-developed biologic drugs in three Phase III pivotal trials. Our goal is to have marketed products in 2007. Alexion is guided by our commitment, determination, focus, and passion for our mission with the objective to achieve successful outcomes for our patients, the healthcare professionals we work with, our employees and our shareholders. For Alexion, Every Day Matters™ in achieving our mission.

Alexion was founded by Drs. Leonard Bell, Steven Squinto and Scott Rollins in 1992 with most of our founding scientists having had an association with Yale University. Dr. Rollins, the inventor of our two lead candidate drugs and Dr. Rother, a founding scientist, have also been associated with the Oklahoma Medical Research Foundation. Since 1996, Alexion has been listed on NASDAQ with the ticker symbol: ALXN.

We lead the world in developing anti-complement therapies; complement cascade is part of the innate immune system and, if successful, Alexion will be the first biopharmaceutical company to have developed and marketed an anti-complement compound. Specifically, Alexion has two internally-developed product candidates, both in pivotal Phase III programs. Eculizumab, a humanized Alexion-engineered anti-C5 complement monoclonal antibody, is being developed for treatment of paroxysmal nocturnal hemoglobinuria. TRIUMPH has completed enrollment and is the pivotal efficacy study, while SHEPHERD, which also has completed enrollment is the Phase III safety study. Pexelizumab, a humanized Alexion-engineered anti-C5 short-chain fragment antibody, is being developed for two indications: reduction of myocardial infarction or death in multi-risk patients undergoing coronary artery bypass graft surgery using cardiopulmonary bypass (CABG-CPB); and, reduction of death in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention (AMI-PCI) procedure, that includes angioplasty and stent placement. Our CABG-CPB trial called PRIMO2 has finished enrollment and is our registration trial (pivotal Phase III). Our second indication trial for AMI-PCI, called APEX, is in the midst of enrollment. If successful, we believe each trial would be sufficient for the registration for two indications for pexelizumab. For all pexelizumab trials as well as its commercial development, we have a productive collaboration with Procter & Gamble Pharmaceuticals with an approximate 50/50 arrangement in the United States.

Our commercial, clinical, regulatory, finance, legal and other headquarter functions are based in Cheshire, Connecticut, just north of New Haven. Our manufacturing facility is in New Haven. Alexion has two research facilities, one in Cheshire, and the other in San Diego, California, called Alexion Antibody Technologies, a wholly owned subsidiary. Both research teams are capable of discovering, engineering and developing novel monoclonal antibodies. Our discovery programs are focused on cancer and immune-related problems that are serious or critical in nature.